Atorvastatin calcium trihydrate | CAS#344423-98-9 | 134523-00-5 | CAS#134523-03-8 | HMG-CoA reductase inhibitor

MedKoo Cat#: 317257 | Name: Atorvastatin calcium trihydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Atorvastatin is used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.Atorvastatin is also used for the treatment of dyslipidemia.

Chemical Structure

Atorvastatin calcium trihydrate

CAS#344423-98-9 (calcium trihydrate)

Theoretical Analysis

MedKoo Cat#: 317257

Name: Atorvastatin calcium trihydrate

CAS#: 344423-98-9 (calcium trihydrate)

Chemical Formula: C66H74CaF2N4O13

Exact Mass: 0.0000

Molecular Weight: 1209.39

Elemental Analysis: C, 65.55; H, 6.17; Ca, 3.31; F, 3.14; N, 4.63; O, 17.20

Price and Availability

Size	Price	Availability
1g	USD 110.00	Ready to ship
2g	USD 150.00	Ready to ship
5g	USD 300.00	Ready to ship
10g	USD 500.00	Ready to ship
25g	USD 950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

134523-03-8 (calcium) 344423-98-9 (calcium trihydrate) 134523-00-5 (free acid) 134523-01-6 (sodium) 874114-41-7 (magnesium) 1035609-19-8 (magnesium trihydrate) 609843-23-4 (lysine) 1072903-92-4 (strontium)

Synonym

CI-981; CI 981; CI981; Atorvastatin; atorvastatin calcium trihydrate; atorvastatin, calcium salt; Brand name: Lipitor; liptonorm

IUPAC/Chemical Name

calcium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate trihydrate

InChi Key

SHZPNDRIDUBNMH-NIJVSVLQSA-L

InChi Code

InChI=1S/2C33H35FN2O5.Ca.3H2O/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;;;;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);;3*1H2/q;;+2;;;/p-2/t2*26-,27-;;;;/m11..../s1

SMILES Code

O=C(NC1=CC=CC=C1)C2=C(N(C(C3=CC=C(C=C3)F)=C2C4=CC=CC=C4)CC[C@H](C[C@H](CC([O-])=O)O)O)C(C)C.O=C(NC5=CC=CC=C5)C6=C(N(C(C7=CC=C(C=C7)F)=C6C8=CC=CC=C8)CC[C@H](C[C@H](CC([O-])=O)O)O)C(C)C.[H]O[H].[H]O[H].[H]O[H].[Ca+2]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#C9R02B15

QC Data

View QC data: current batch, Lot#C9R02B15

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	165.37

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,209.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Delgado-Montero A, Zamorano JL. Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opin Pharmacother. 2012 Dec;13(18):2673-85. doi: 10.1517/14656566.2012.742064. Review. PubMed PMID: 23140185. 2: Goriacko P, Andersen M, Fazylov R, Plakogiannis R. What Is the Appropriate Duration of High-Dose Atorvastatin Therapy Post-Acute Coronary Syndrome? J Pharm Pract. 2015 Dec;28(6):555-60. Review. PubMed PMID: 25107416. 3: Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. Eur J Prev Cardiol. 2016 May;23(7):744-7. doi: 10.1177/2047487315598710. Review. PubMed PMID: 26246463. 4: Li H, Wang C, Zhang S, Sun S, Li R, Zou M, Cheng G. Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants. Drug Saf. 2016 May;39(5):409-19. doi: 10.1007/s40264-016-0394-0. Review. PubMed PMID: 26860922. 5: Fang N, Han W, Gong D, Zou Chen, Fan Y. Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes: A Meta-Analysis. Medicine (Baltimore). 2015 Nov;94(44):e1920. doi: 10.1097/MD.0000000000001920. Review. PubMed PMID: 26554793; PubMed Central PMCID: PMC4915894. 6: Qian C, Wei B, Ding J, Wu H, Cai X, Li B, Wang Y. Meta-analysis comparing the effects of rosuvastatin versus atorvastatin on regression of coronary atherosclerotic plaques. Am J Cardiol. 2015 Nov 15;116(10):1521-6. doi: 10.1016/j.amjcard.2015.08.010. Review. PubMed PMID: 26385518. 7: Blank R. A single-pill combination of amlodipine besylate and atorvastatin calcium. Drugs Today (Barc). 2006 Mar;42(3):157-75. Review. PubMed PMID: 16628258. 8: Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015 Mar 12;(3):CD008226. doi: 10.1002/14651858.CD008226.pub3. Review. PubMed PMID: 25760954. 9: Ye YC, Zhao XL, Zhang SY. Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients. Chin Med J (Engl). 2015 Jan 20;128(2):259-66. doi: 10.4103/0366-6999.149226. Review. PubMed PMID: 25591572; PubMed Central PMCID: PMC4837848. 10: Dai G, Xu Q, Luo R, Gao J, Chen H, Deng Y, Li Y, Wang Y, Yuan W, Wu X. Atorvastatin treatment improves effects of implanted mesenchymal stem cells: meta-analysis of animal models with acute myocardial infarction. BMC Cardiovasc Disord. 2015 Dec 14;15:170. doi: 10.1186/s12872-015-0162-6. Review. PubMed PMID: 26667804; PubMed Central PMCID: PMC4678482. 11: Takagi H, Niwa M, Mizuno Y, Yamamoto H, Goto SN, Umemoto T. Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials. Heart Vessels. 2014 May;29(3):287-99. doi: 10.1007/s00380-013-0358-6. Review. PubMed PMID: 23644555. 12: Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group.. A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles. Am J Cardiol. 2014 Jan 15;113(2):292-301. doi: 10.1016/j.amjcard.2013.08.043. Review. PubMed PMID: 24230979. 13: Yang Q, Qi X, Li Y. The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2014 Aug 13;14:99. doi: 10.1186/1471-2261-14-99. Review. PubMed PMID: 25117689; PubMed Central PMCID: PMC4135360. 14: Simoens S, Sinnaeve PR. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy. Cardiovasc Drugs Ther. 2013 Feb;27(1):49-60. doi: 10.1007/s10557-012-6432-y. Review. PubMed PMID: 23242669. 15: Adams SP, Tsang M, Wright JM. Lipid lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2012 Dec 12;12:CD008226. doi: 10.1002/14651858.CD008226.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;3:CD008226. PubMed PMID: 23235655. 16: Violi F, Carnevale R, Pastori D, Pignatelli P. Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends Cardiovasc Med. 2014 May;24(4):142-8. doi: 10.1016/j.tcm.2013.09.006. Review. PubMed PMID: 24263084. 17: Poolsup N, Suksomboon N, Wongyaowarat K, Rungkanchananon B, Niyomrat P, Kongsuwan S. Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. J Clin Pharm Ther. 2012 Apr;37(2):166-72. doi: 10.1111/j.1365-2710.2011.01274.x. Review. PubMed PMID: 21585411. 18: Liu M, Alafris A, Longo AJ, Cohen H. Irreversible atorvastatin-associated hearing loss. Pharmacotherapy. 2012 Feb;32(2):e27-34. doi: 10.1002/PHAR.1040. Review. PubMed PMID: 22392429. 19: McKenney JM. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. Postgrad Med. 2012 Jan;124(1):7-20. doi: 10.3810/pgm.2012.01.2513. Review. PubMed PMID: 22314110. 20: DiNicolantonio JJ, Lavie CJ, Serebruany VL, O'Keefe JH. Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgrad Med. 2013 Jan;125(1):7-16. doi: 10.3810/pgm.2013.01.2620. Review. PubMed PMID: 23391667.